This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...

The drug, sold under the brand name Kisunla and produced by drugmaker Eli Lilly, slows down the disease by up to 35%, ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Recent health developments include Eli Lilly's Alzheimer's treatment approval in China, a DOJ lawsuit against CVS for opioid ...

Minnesota Alzheimer's patients will be among the first to receive a new treatment through the drug Kisunla, which targets the ...

FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...

Donanemab, sold under the brand name Kisunla, has proven to be able to halt Alzheimer's by as much as 35%.

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic Alzheimer’s ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.